Retatrutide Half-Life and Pharmacokinetics

Retatrutide's half-life — the short version

Retatrutide has a half-life of approximately 6 days. A half-life is the time it takes for the amount of a drug in the blood to fall to half its peak level — a longer half-life means the drug clears more slowly and stays active longer. The 6-day half-life was established in Eli Lilly's Phase 1b trial ^[4] and is the pharmacokinetic property that makes once-weekly injections feasible.

In practice: after a single dose, blood levels remain pharmacologically meaningful for roughly 3–4 weeks before falling to negligible concentrations. After 4–5 weeks of once-weekly dosing, concentrations stabilize in a steady-state band — the level stays relatively constant between weekly injections, neither accumulating indefinitely nor dropping too low between doses.

The retatrutide half life figure of ~6 days compares to roughly 1 week for semaglutide (another GLP-1-class investigational/approved agent) — meaning both support once-weekly dosing through similar pharmacokinetic logic, though the structural basis for each is different. Retatrutide's extended half-life is achieved through fatty-acid acylation — a C20 fatty-diacid chain — that binds the peptide to albumin (a blood protein), slowing renal clearance.

Phase 1b pharmacokinetics: the primary data

Urva S et al., The Lancet, 2022 ^[4]. 72 adults with type 2 diabetes (HbA1c 7.0–10.5%); multiple-ascending-dose design; subcutaneous once weekly over 12 weeks.

Doses studied: 0.5 mg, 1.5 mg, 3 mg, 3/6 mg (escalation), and 3/6/9/12 mg (full escalation).

Pharmacokinetic findings:

• Half-life: ~6 days (estimated from plasma concentration-time profiles; supports once-weekly dosing).
• Time to peak concentration (Tmax): approximately 24–72 hours after subcutaneous injection in the Phase 1b data.
• Absorption: subcutaneous injection into fatty tissue; absorbed into systemic circulation; albumin binding via the acyl chain prolongs circulating half-life.

Pharmacodynamic outcomes at highest dose (3/6/9/12 mg):

• Placebo-adjusted weight change: -8.96 kg (90% CI: -11.16 to -6.75 kg) over 12 weeks.
• Daily glucose reduction: -2.8 mmol/L at 3 mg.

Treatment-emergent adverse events: 63% of participants, predominantly GI in nature. The safety profile was characterized as acceptable and the half-life results supported advancement to Phase 2.

What the fatty-acid acylation does — the structural basis of the half-life

Retatrutide's 39-amino-acid peptide backbone is built on a GIP-based sequence. The extended half-life is not intrinsic to that backbone — it is conferred by a C20 fatty-diacid chain (a fatty acid with 20 carbon atoms attached to a diacid linker) chemically bonded to a lysine residue in the peptide chain ^[3].

The mechanism: the acyl chain reversibly binds to albumin (the most abundant protein in blood plasma). Albumin-bound retatrutide is too large to be filtered by the kidneys and too protected from enzyme degradation to clear quickly. As free retatrutide concentration falls, the albumin-retatrutide complex releases more free drug — a slow-release depot effect that extends the effective half-life to ~6 days.

This is the same structural strategy used in other acylated peptide drugs (semaglutide also uses albumin binding via a fatty-acid linker). Retatrutide's specific acylation chemistry was designed to optimize the balance between long half-life (desirable for once-weekly dosing) and minimizing unintended off-target effects from prolonged receptor exposure.

Cryo-EM structural studies published in 2024 resolved retatrutide's binding at all three receptors at near-atomic resolution, confirming the receptor-engagement geometry that the pharmacokinetics support ^[3].

Once-weekly dosing: what the PK profile means in practice

A half-life of ~6 days with a weekly dosing interval means that by the time of the next injection (7 days after the previous one), approximately 30% of the prior dose remains in circulation (after one half-life, 50% remains; after one half-life plus a fraction, somewhat less). At steady state — reached after approximately 4–5 weeks of weekly dosing — peak and trough concentrations stabilize into a consistent band.

This steady-state profile is why retatrutide's Phase 2 trials used 48-week durations: the compound needs several weeks to reach equilibrium concentrations before its full dose-response relationship can be measured. Early weight loss in the Phase 2 trial was detectable from the first weeks, but the trajectory continued through week 48 without plateauing, suggesting the full extent of weight reduction at 12 mg had not been reached.

For a broader account of the mechanism driving those outcomes, see how does retatrutide work.

Steady state, accumulation, and dosing windows

Accumulation: With a 6-day half-life and 7-day dosing interval, a small degree of accumulation occurs in the first weeks of once-weekly dosing — each new dose arrives before the prior dose has fully cleared. By weeks 4–5, the accumulation factor stabilizes and a true steady state is reached. In Phase 2, the structured dose-escalation schedules were designed to manage this accumulation pattern alongside tolerability.

Missed dose: Because the half-life is ~6 days, a missed single weekly injection does not produce abrupt loss of effect. The plasma concentration falls gradually. This is a pharmacokinetic property, not a dosing recommendation.

Injection site and absorption rate: All Phase 1/2 studies used subcutaneous injection. Subcutaneous absorption is generally slower than intravenous but faster than oral for peptides of this size. The time to peak concentration of approximately 24–72 hours post-injection reflects the absorption phase from the subcutaneous depot before the drug enters systemic circulation.

For the research context on the dose levels used across trials, see the Retatrutide research page.